文献速递胸部肿瘤

晚期非小细胞肺癌抗PD-1治疗患者预存抗体特征分析

Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2019-01-01

该回顾性病历分析纳入2016年1月至2018年1月在日本仙台厚生医院接受纳武利尤单抗或帕博利珠单抗单药治疗的137例晚期非小细胞肺癌患者,评估预存自身免疫标志物与疗效及免疫相关不良事件的关系。预存抗体阳性者中位无进展生存期6.5个月(95%CI 4.4-12.9),阴性者3.5个月(95%CI 2.4-4.1),疾病进展或死亡风险比为0.53(95%CI 0.36-0.79;P=0.002)。预存抗体与免疫相关不良事件独立相关(比值比3.25;95%CI 1.59-6.65;P=0.001)。

要点

  • 预存抗体阳性者中位无进展生存期6.5个月,阴性者3.5个月,风险比0.53(95%CI 0.36-0.79;P=0.002)。
  • 预存抗体与免疫相关不良事件独立相关(比值比3.25;95%CI 1.59-6.65;P=0.001)。
  • 类风湿因子阳性者皮肤反应更常见(47% vs 24%,P=0.02),抗甲状腺抗体阳性者甲状腺功能障碍更常见(20% vs 1%,P<0.001)。

核心结论

  • 所检测的预存抗体与纳武利尤单抗或帕博利珠单抗治疗的晚期非小细胞肺癌患者的临床获益及免疫相关不良事件发生相关。
  • 这些自身免疫标志物的存在可能有助于判断个体患者的风险获益比,最大化治疗获益并减少免疫相关不良事件。

研究设计与样本

  • 该研究为回顾性病历分析,纳入2016年1月至2018年1月在日本仙台厚生医院接受纳武利尤单抗或帕博利珠单抗单药治疗的137例晚期非小细胞肺癌患者。
  • 137例中男性105例,中位年龄68岁(范围36-88岁),99例接受纳武利尤单抗单药治疗,38例接受帕博利珠单抗单药治疗,134例美国东部肿瘤协作组体能状态评分为0或1。
  • 暴露因素为治疗前特定自身免疫标志物和抗体的存在与否,主要结局为预存抗体和自身免疫标志物、无进展生存期及免疫相关不良事件。

主要发现

  • 检测预存抗体患者的中位无进展生存期为6.5个月(95%CI 4.4-12.9),未检测到预存抗体患者为3.5个月(95%CI 2.4-4.1),前者预后显著更好。
  • 存在所检测预存抗体时疾病进展或死亡的风险比为0.53(95%CI 0.36-0.79;P=0.002)。
  • 发生免疫相关不良事件的患者中,所检测预存抗体更常见(48例[73%]),类风湿因子也更常见(26例[39%])。
  • 多因素分析显示,所检测预存抗体的存在与免疫相关不良事件独立相关(比值比3.25;95%CI 1.59-6.65;P=0.001)。
  • 预存类风湿因子阳性者皮肤反应更频繁(47% vs 24%,P=0.02),预存抗甲状腺抗体阳性者甲状腺功能障碍更频繁(20% vs 1%,P<0.001)。

关键数值与推荐

  • 所检测预存抗体阳性患者中位无进展生存期6.5个月(95%CI 4.4-12.9),阴性患者3.5个月(95%CI 2.4-4.1)。
  • 存在所检测预存抗体时疾病进展或死亡的风险比为0.53(95%CI 0.36-0.79;P=0.002)。
  • 所检测预存抗体与免疫相关不良事件的比值比为3.25(95%CI 1.59-6.65;P=0.001)。
  • 类风湿因子阳性者皮肤反应发生率为47%(vs 24%,P=0.02)。
  • 抗甲状腺抗体阳性者甲状腺功能障碍发生率为20%(vs 1%,P<0.001)。

临床怎么用

  • 原文结论指出这些自身免疫标志物的存在可能有助于判断个体非小细胞肺癌患者的风险获益比,以最大化治疗获益并减少免疫相关不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Administration of anti-programmed cell death protein 1 (anti-PD-1) is now standard therapy in advanced non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors, including anti-PD-1, have not been assessed in patients with subclinical disease with advanced NSCLC, and no useful clinical biomarkers have been associated with immune-related adverse events (irAEs) among these patients treated with anti-PD-1. OBJECTIVE: To assess the safety and efficacy of anti-PD-1 treatment in patients with subclinical disease with advanced NSCLC and with or without preexisting autoimmune markers, including rheumatoid factor, antinuclear antibody, antithyroglobulin, and antithyroid peroxidase; and to assess potential clinical biomarkers that may be meaningfully and conveniently associated with clinical benefit or with irAEs following anti-PD-1 treatment. DESIGN, SETTING, AND PARTICIPANTS: This medical records analysis retrospectively evaluated 137 patients who received nivolumab or pembrolizumab monotherapy at Sendai Kousei Hospital in Japan between January 2016 and January 2018. Treatment efficacy and irAEs were evaluated along with candidate factors that may be associated with irAEs. EXPOSURES: Absence or presence of specific autoimmune markers and antibodies before treatment. MAIN OUTCOMES AND MEASURES: Preexisting antibodies and autoimmune markers, progression-free survival (PFS), and irAEs. RESULTS: Of 137 patients with advanced NSCLC, 105 were men, the median age was 68 (range, 36-88) years, 99 underwent nivolumab monotherapy, 38 underwent pembrolizumab monotherapy, and 134 had an Eastern Cooperative Oncology Group performance status of 0 or 1. The median PFS was 6.5 (95% CI, 4.4-12.9) months among patients with examined preexisting antibodies and 3.5 (95% CI, 2.4-4.1) months among patients without, suggesting significantly better prognosis in the former. The hazard ratio for disease progression or death in the presence of the examined preexisting antibodies was 0.53 (95% CI, 0.36-0.79; P = .002). The PFS was significantly longer among patients with any preexisting antibodies than among those without. The examined preexisting antibodies (48 patients [73%]) and rheumatoid factor (26 patients [39%]) were more common among patients who developed irAEs. Multivariate analysis indicated that the presence of the examined preexisting antibodies was independently associated with irAEs (odds ratio, 3.25; 95% CI, 1.59-6.65; P = .001). Skin reactions were more frequent among patients with preexisting rheumatoid factor (47% vs 24%, P = .02), whereas thyroid dysfunction was more frequent among patients with preexisting antithyroid antibodies (20% vs 1%, P < .001). CONCLUSIONS AND RELEVANCE: The presence of the examined preexisting antibodies was associated with clinical benefit and with the development of irAEs in patients with NSCLC treated with nivolumab or pembrolizumab. Thus, the presence of these autoimmune markers may help determine the risk-benefit ratio for individual patients with NSCLC, maximizing therapeutic benefits while minimizing irAEs.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Toi Y, Sugawara S, Sugisaka J, et al. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2019. PMID: 30589930. doi:10.1001/jamaoncol.2018.5860

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。